PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.
OBJECTIVE
Previous studies have shown that peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor expressed in vascular cells, is protective of the vasculature. We hypothesized that activation of PPARgamma could prevent hypertensive remodeling of cerebral arteries and improve vascular function.


METHODS
Ten female Sprague-Dawley rats were treated with the nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester (l-NAME) for 5 weeks, 8 were treated with l-NAME plus the PPARgamma activator rosiglitazone, and 8 received no treatment and served as controls. Blood pressure, myogenic activity, passive diameters and wall thickness of cerebral arteries, and brain capillary density were compared between the groups.


RESULTS
Treatment with l-NAME caused an increase in arterial blood pressure that was sustained with rosiglitazone treatment. l-NAME also caused inward hypertrophic remodeling and enhanced myogenic reactivity of cerebral arteries that was reversed by rosiglitazone. In addition, l-NAME hypertension caused rarefaction of brain capillaries by approximately 12%, whereas treatment with rosiglitazone increased capillary density by approximately 20%.


CONCLUSIONS
PPARgamma activation may be an effective and clinically relevant way to prevent hypertensive remodeling of cerebral arteries and capillary rarefaction as well as improving vascular function without affecting blood pressure.
Cipolla
Marilyn J
MJ
Department of Neurology, University of Vermont, 89 Beaumont Avenue, Given C454, Burlington, VT 05405, USA. Marilyn.Cipolla@uvm.edu
Bishop
Nicole
N
Vinke
R Saman
RS
Godfrey
Julie A
JA
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000098:blood supply / Q000503:physiopathology; D002196:Capillaries / Q000503:physiopathology; D002536:Cerebral Arteries / Q000378:metabolism / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D019331:NG-Nitroarginine Methyl Ester
Hypertension. 1988 Aug;12(2):89-95
3044994
Circulation. 2009 Mar 3;119(8):1124-34
19221220
Diabetes. 2008 May;57(5):1394-404
18268046
PPAR Res. 2008;2008:527048
18288290
Circulation. 2002 May 14;105(19):2296-302
12010913
J Clin Invest. 1996 Oct 15;98(8):1897-905
8878442
J Hypertens Suppl. 1992 Dec;10(7):S71-5
1291659
Hypertension. 2008 Apr;51(4):867-71
18285614
Circ Res. 2008 Feb 15;102(3):283-94
18276926
Endocrinology. 2001 Jul;142(7):3125-34
11416035
Biomed Pharmacother. 2008 Jan;62(1):46-52
17692499
Front Biosci. 2008 Jan 01;13:1813-26
17981670
Stroke. 2004 Jul;35(7):1726-31
15143297
J Cereb Blood Flow Metab. 2010 Apr;30(4):827-36
19953101
Stroke. 2006 Mar;37(3):894-9
16456123
Hypertension. 2004 Mar;43(3):661-6
14744930
J Neurosci. 2008 Sep 10;28(37):9287-96
18784309
Stroke. 2007 Nov;38(11):3016-22
17885259
Microvasc Res. 1985 Jul;30(1):1-9
4021832
Stroke. 2009 Mar;40(3 Suppl):S92-4
19064796
Hypertension. 2008 Apr;51(4):1052-7
18259042
Drugs. 1999;59 Spec No:1-10
10548386
Hypertension. 2007 Jul;50(1):14-24
17548723
Circulation. 1987 Jun;75(6 Pt 2):V65-73
3568338
J Hypertens. 2005 May;23(5):1061-6
15834293
Brain Res. 2006 Jun 6;1093(1):208-18
16696956
Lancet. 1993 Jun 5;341(8858):1447-51
8099148
Cell Metab. 2008 Mar;7(3):215-26
18316027